Detalles de la búsqueda
1.
TimeTeller: A tool to probe the circadian clock as a multigene dynamical system.
PLoS Comput Biol
; 20(2): e1011779, 2024 Feb.
Artículo
en Inglés
| MEDLINE | ID: mdl-38422117
2.
Efficacy and safety of lenvatinib plus pembrolizumab vs sunitinib in the East Asian subset of patients with advanced renal cell carcinoma from the CLEAR trial.
Int J Cancer
; 153(6): 1241-1250, 2023 09 15.
Artículo
en Inglés
| MEDLINE | ID: mdl-37294085
3.
A comparison of sunitinib with cabozantinib, crizotinib, and savolitinib for treatment of advanced papillary renal cell carcinoma: a randomised, open-label, phase 2 trial.
Lancet
; 397(10275): 695-703, 2021 02 20.
Artículo
en Inglés
| MEDLINE | ID: mdl-33592176
4.
Local control and patterns of failure for "Radioresistant" spinal metastases following stereotactic body radiotherapy compared to a "Radiosensitive" reference.
J Neurooncol
; 152(1): 173-182, 2021 Mar.
Artículo
en Inglés
| MEDLINE | ID: mdl-33453002
5.
The financial impact of cancer care on renal cancer patients.
Can J Urol
; 28(4): 10762-10767, 2021 08.
Artículo
en Inglés
| MEDLINE | ID: mdl-34378512
6.
Real-World Assessment of Clinical Outcomes Among First-Line Sunitinib Patients with Clear Cell Metastatic Renal Cell Carcinoma (mRCC) by the International mRCC Database Consortium Risk Group.
Oncologist
; 25(5): 422-430, 2020 05.
Artículo
en Inglés
| MEDLINE | ID: mdl-31971318
7.
Development and Implementation of a Continuing Medical Education Program in Canada: Knowledge Translation for Renal Cell Carcinoma (KT4RCC).
J Cancer Educ
; 34(1): 14-18, 2019 02.
Artículo
en Inglés
| MEDLINE | ID: mdl-28779441
8.
Cabozantinib versus Everolimus in Advanced Renal-Cell Carcinoma.
N Engl J Med
; 373(19): 1814-23, 2015 Nov 05.
Artículo
en Inglés
| MEDLINE | ID: mdl-26406150
9.
The prognostic and predictive value of vascular response parameters measured by dynamic contrast-enhanced-CT, -MRI and -US in patients with metastatic renal cell carcinoma receiving sunitinib.
Eur Radiol
; 28(6): 2281-2290, 2018 Jun.
Artículo
en Inglés
| MEDLINE | ID: mdl-29383520
10.
The future of precise cancer chronotherapeutics.
Lancet Oncol
; 23(6): e242, 2022 06.
Artículo
en Inglés
| MEDLINE | ID: mdl-35654059
11.
Relationship between subjective and actigraphy-measured sleep in 237 patients with metastatic colorectal cancer.
Qual Life Res
; 26(10): 2783-2791, 2017 10.
Artículo
en Inglés
| MEDLINE | ID: mdl-28656534
12.
The effect of melatonin on sleep and quality of life in patients with advanced breast cancer.
Support Care Cancer
; 24(3): 1097-105, 2016 Mar.
Artículo
en Inglés
| MEDLINE | ID: mdl-26260726
13.
miR-221/222 Are Involved in Response to Sunitinib Treatment in Metastatic Renal Cell Carcinoma.
Mol Ther
; 23(11): 1748-1758, 2015 Nov.
Artículo
en Inglés
| MEDLINE | ID: mdl-26201448
14.
The International Metastatic Renal Cell Carcinoma Database Consortium model as a prognostic tool in patients with metastatic renal cell carcinoma previously treated with first-line targeted therapy: a population-based study.
Lancet Oncol
; 16(3): 293-300, 2015 Mar.
Artículo
en Inglés
| MEDLINE | ID: mdl-25681967
15.
Sunitinib-associated hypertension and neutropenia as efficacy biomarkers in metastatic renal cell carcinoma patients.
Br J Cancer
; 113(11): 1571-80, 2015 Dec 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-26492223
16.
Quantitative proteomic analysis in metastatic renal cell carcinoma reveals a unique set of proteins with potential prognostic significance.
Mol Cell Proteomics
; 12(1): 132-44, 2013 Jan.
Artículo
en Inglés
| MEDLINE | ID: mdl-23082029
17.
Dovitinib versus sorafenib for third-line targeted treatment of patients with metastatic renal cell carcinoma: an open-label, randomised phase 3 trial.
Lancet Oncol
; 15(3): 286-96, 2014 Mar.
Artículo
en Inglés
| MEDLINE | ID: mdl-24556040
18.
Lactate dehydrogenase A is a potential prognostic marker in clear cell renal cell carcinoma.
Mol Cancer
; 13: 101, 2014 May 05.
Artículo
en Inglés
| MEDLINE | ID: mdl-24885701
19.
External validation and comparison with other models of the International Metastatic Renal-Cell Carcinoma Database Consortium prognostic model: a population-based study.
Lancet Oncol
; 14(2): 141-8, 2013 Feb.
Artículo
en Inglés
| MEDLINE | ID: mdl-23312463
20.
Association of Cabozantinib Dose Reductions for Toxicity With Clinical Effectiveness in Metastatic Renal Cell Carcinoma (mRCC): Results From the Canadian Kidney Cancer Information System (CKCis).
Clin Genitourin Cancer
; : 102060, 2024 Feb 23.
Artículo
en Inglés
| MEDLINE | ID: mdl-38521648